Conference series takes pleasure in inviting the scientific community across the globe to attend the 12th European Biosimilars Congressduring April 15-16, 2019atBerlin, Germanywith a motto to Explore Innovations in Biosimilars & Biologics.This European Biosimilars Congress 2019 will bring together Professors, scientists, researchers, business development managers, CEOs, directors, IP Attorneys, Regulatory Officials, CROs and students from around the world. The passage of biosimilars through a decade at Europe finds much requirement for discussion also focussing the latest developments in the field of biologics and biosimilars.
Kamali Chance, BioSciencesCorp, USA; Cecil Nick, PAREXEL International, UK; David Ebsworth,
ViforPharma Ltd, Switzerland;ParastooAzadi, Complex Carbohydrtae Research Center – University of Georgia, USAFiona M Greer, SGS Life Sciences, Switzerland; András Guttman, SCIEX, USA; Dominic Seitz, Simon-Kucher& Partners, Germany; Rosa Helena Bustos, University of La Sabana, Colombia; Sakae Tsuda, National Institute of Advanced Industrial Science and Technology, Japan; Menachem Zucker, E3D Elcam Drug Delivery Devices, Israel; Victor Tsetlin, ShemyakinOvchinnikov Institute of Bioorganic Chemistry RAS, Russia; Archana Shubhakar, Ludger Ltd, UK; Kurt R Karst, Hyman, Phelps & McNamara, PC, USA
Euro Biosimilars 2019Conference will encourage Young Researcher’s Forum, scientists and the researchers in their early stage of career graph to widely discuss their outcome so as to enrich and develop the idea. The ‘Best Poster Award’ is meant to encourage students in taking active part in the International Science platform to sharpen their skills and knowledgebase.
The important tracks that are part of Euro Biosimilars 2019include:
Current Challenges in Developing Biosimilars, Emerging Biosimilars in Therapeutics, Analytical Strategies for Biosimilars, Regulatory Approach of Biosimilars, Biosimilar Companies and Market Analysis, Innovative Approach for Biosimilars, Clinical Development of Biosimilars, Consequences of Brexit on Biosimilars, Intellectual Property Rights, Globalization of Biosimilars, Bioequivalence Assessment, Biosimilars Research Pipeline, BCS and IVIVC Based Biowaivers, Biosimilar Market and Cost Analysis, Challenges in Biosimilars Pharmacovigilance, Legal Issues and BPCI Act,
Euro Biosimilars 2019 is comprised of 22 tracks and 90 sessions designed to offer comprehensive sessions that address current issue. For more scientific sessions and abstractsubmission, please visit:https://goo.gl/YYPkyu
The Abstracts that are accepted for presentations are published in the proceedings of the Journals likeJournal of Bioanalysis & Biomedicine, Journal of Bioequivalence & Bioavailability
Grab the opportunity to participate by registering through flowing link:
http://biosimilars-biologics.pharmaceuticalconferences.com/europe/registration.php
